Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a ...

Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright ...

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts disc ...

H.C. Wainwright maintains a Buy rating on Invivyd (IVVD) with a $10 price target after the FDA rejected its submission to expand Pemgarda’s ...

Invivyd's bid to expand Pemgarda's EUA for COVID-19 treatment was denied by the FDA. The company will share new data on ...

In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Invivyd (IVVD – Research Report), with a price ...

Los Angeles Chargers head coach Jim Harbaugh shared his view on the controversial tush push, saying teams either have to "get ...

The commercial-stage biopharmaceutical company said its request to expand the existing emergency use authorization of the drug, also called pemivibart, to treat mild-to-moderate Covid-19 in more ...

Los Angeles Chargers head coach Jim Harbaugh truly lives by "faith, family, football," and he called it "inspiring" to see other NFL stars so open about doing the same.

Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual ...

Find insight on Smith & Nephew, Raffles Medical Group and more in the latest Market Talks covering the Health Care sector.